Sign in

CIK 0001374690

  • Non-accelerated filer
  • Smaller reporting company

Larimar Therapeutics, Inc.

Sign in to watch
Ticker
LRMR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
203857670
Phone
+1 844-511-9056
Business address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
Former names
ZAFGEN, INC., ZAFGEN INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market buy Director bought 57,208 shares at $8.74 ($499,998)
  3. 4 Open-market buy Director bought 4,290,617 shares at $8.74 ($37,499,993)
  4. 4 Open-market buy Director bought 2,000 shares at $11.00 ($22,000)
  5. 4 Grant or award Chief Development Officer acquired 22,500 shares (grant or award)
  6. 4 Grant or award Chief Financial Officer acquired 31,250 shares (grant or award)
  7. 4 Grant or award Chief Medical Officer acquired 22,500 shares (grant or award)
  8. 4 Grant or award President and CEO acquired 66,125 shares (grant or award)
  9. 4 Open-market buy Chief Development Officer bought 5,000 shares at $3.73 ($18,662)
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Derivatives Options or other derivatives
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market buy Chief Financial Officer bought 5,000 shares at $3.73 ($18,632)
  15. 4 Open-market buy President and CEO bought 5,000 shares at $3.71 ($18,525)
  16. 4 Open-market buy Director bought 2,750 shares at $3.73 ($10,258)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 3 of 14 · 272 filings